Call Us @ 0172 - 4680800 | | NETWORKS | NSE - BSE

 Ind-Swift has made a marked presence in the national and international market, for more than two decades.

 It has a strong global network in more than 50 countries.


 Ind-Swift has a workforce of over 3000 multifunctional and multicultural employees, motivated towards higher standards of customer satisfaction.

 3200+ Stockists accross India serving over 60 Lakh customers.

 Long term supply alliances with reputed global companies in the markets of the US, Europe, Middle East, South East Asia and Africa.

 Joint ventures and subsidiaries in Iran, Singapore and Dubai, for establishing a good network for international marketing.

 A strong presence in Europe, Middle East, US and CIS Countries.

 A strong prescribing doctor’s base of over 2.50Lacs.

 Ind-Swift possesses a portfolio of over 750 products.

 It has a marked presence in high growth therapeutic segments of Cardiology, Diabetology, Anti-depressant, Anti-allergic, Anti-Infective, Neurology and Oncology.

 It is the world's largest manufacturer of Clarithromycin, Azithromycin and Fexofenadine.


 Ind-Swift is ranked 90th among the top Indian Pharmaceutical companies in India.

 It is among the fortune 500 companies of India.

 It is ranked the 101st largest pharma company in the global market by Plimsoll Global Analysis.


Ind-Swift has been bestowed with many prestigious awards. A few of them are::

 Most promising entrant into the big league, award at the 5th Annual Pharmaceutical Leadership Summit & Business Leadership Award 2012 held in Mumbai on 21 September, 2012

 Pharma Pulse Award for three consecutive years (2002-2005).

 Bharat Udhyog Rattan Award.

 IDMA (Indian Drug Manufacturers Association) Quality Excellence Award.

 Deloitte Technology fast 500 Asia pacific Award in 2006 by Deloitte .

 Udyog Rattan Award for valuable contributions to the economic development of Himachal Pradesh.

 Certificate of Excellence in recognition of Exemplary Growth and Sustainable Success by India Brand Equity Federation in the Second Annual Inc. India 500 Award.


Ind-Swift possesses state-of-the-art manufacturing facilities for finished Dosage Forms & API's conforming to the most stringent international norms of WHO-GMP, TGA (Australia), MHRA (UK).

Ind-Swift has a manufacturing capacity of (Finished Dosage) :

  • 2300 million Tablets
  • 64 million Ampoules
  • 27 million Vials
  • 84 million Capsules
  • 18 million Dermatological products
  • 62 million Oral liquid bottles

Manufacturing capacity (API) :

  • 1,50,0000 (15 lakhs) sq. ft. covered area.
  • 11 Dedicated blocks operating as per USFDA guidelines.
  • 700 Stainless Steel and Glass Lined Reaction Vessels with capacities ranging from 50 to 6000 liters. (Total Volume 1000 kilo liters).
  • 3 Automated Fluidized bed coaters with capacity of manufacturing 4 Metric tonn of Granules per month.
  • CGMP pilot plant having 10 reaction vessels with capacities ranging from 250 to 1000 liters( Total volume 5.5 kilo-liters).
  • Fully Automated Solvent Recovery System.
  • Biological waste water treatment plant.
  • Approvals from TGA (Australia), USFDA, WHO-GMP, MHRA(UK),NDA (Uganda),TFDA(Tanzania),UAEC, DACA-(Ethiopia),GMP(Yemen).

Ind-Swift has an R & D facility duly approved by the Department Of Science of Technology and the Govt of India. This facility has eight synthetic labs with over 40,000 Sq ft of research area and the best pool of scientists and researchers.

Major Break Throughs

 Ind-Swift has filed more than 680 dossiers for registration in more than 20 Countries around the world stretching from South America to Philippines.

 It has developed Netazoxanide Anti-Diarrheal drug for the first time in India after successful clinical trials and bio-equivalence studies.

 It has strong capacity to develop non infringing API's requiring Complex Chemistry and Multiple reactions.

 Ind-Swift has developed taste masking technology of macrolides for the first time in India.

 Ind-Swift has developed the sustained release process of Isoxsuprine HCL tablets for the first time in India.

 Ind-Swift has developed the mouth desolving tablet.

Product In Pipeline

API's in Pipeline
Fluvastatin (Anti Hyperlipidimic)
Risedronate (Osteoporosis)
Acamprosate (AntiAlcoholism)
Montelukast Na (Anti Asthmatic)
Cinacalcet (Hyperparathyroidism)
Duloxetine (Mental Depression)
Naratriptan HCl (Anti Migraine)

 Drug regulatory affair and documentation: Dossiers for ANDA's of different countries, NDA's filing in India, patents filing after a thorough scrutiny by attorneys, documentation for getting USFDA, documentation for R & D products, documentation for commercial samples, documentation for bioequivalence samples